LDS/Medical Tests/Rhesus D (Rh D) Genetic Analysis

Rhesus D (Rh D) Genetic Analysis

Rhesus D (Rh D) hemolytic disease is a disorder that results in incompatibility of blood between mother and fetus. This incompatibility causes sensitization (immune response) if the mother is Rh negative and the fetus is Rh positive. If the fetus’s Rh-positive blood mixes with the mother’s Rh-negative blood (e.g., at delivery), the mother’s immune system will produce antibodies to the Rh (D) factor. Future pregnancies involving an Rh-positive fetus would likely result in hemolytic Rh disease in the baby. Fetal Rh D testing can allow Rh-negative mothers with an Rh-positive fetus to be given an Rh immune globulin prophylaxis to prevent formation of anti-D in the mother and the safety of future fetuses.

PCR-based Rh D genotyping is used to differentiate mutated Rh D genes and a pseudogene sometimes found in people of African descent. The incidence of Rh D negativity is 15% in European descent, 3-5% in African Americans, and less than 1% in Asians. Rh antigen expression involves two genes, RHD and RHCE, located on chromosome 1. Rh D genotyping differentiates between RHD and the pseudogene RHCE. The genotyping identifies various RHD alleles resulting from rearrangements and/or deletions within the gene. An individual’s ethnic background is important in interpreting the results of Rh D genotyping. For example, the majority of Caucasian Rh D negative individuals have a deletion of the RHD gene (thus Rh-negative) and produce the anti-D antibody when exposed to Rh-positive blood. Africans with a negative Rh phenotype based on Rh D genotyping often do not produce the anti-D antibody when exposed to Rh-positive blood. The African allele has been shown to be an Rh D-pseudogene (RHCE) and will present as a false positive result.

  • Determine maternal-fetal Rh D antigen incompatibility
  • Determine fetal Rh D status
  • Assess need for administration of Rh Immune Globulin

Incidence of Rh D negative genotype is higher among Europeans and North Americans of European descent and somewhat less so among African-Americans.

Increased risk:

  • Previous miscarriage, abortion, or ectopic pregnancy and did not receive Rh immune globulin
  • Following injury to fetus or fetomaternal hemorrhage during pregnancy
  • Medical procedures such as amniocentesis or chorionic villus sampling and did not receive Rh immune globulin. Those procedures could let the mother’s blood mix with baby’s blood
  • Mother is Rh-negative and father is Rh-positive

Decreased risk:

  • Mother and father are Rh-negative
  • See the interpretative report provided by the laboratory performing genetic analysis

Rh D negative genotype
Rh D positive genotype

 

 

Real-time polymerase chain reaction (PCR), transcription mediated amplification (TMA), other molecular methods.

Maternal specimens: Whole blood in anticoagulant (EDTA). 

Prenatal testing may be performed using maternal plasma and serum, depending on the laboratory performing test.

Prenatal specimens: Chorionic villus (CV), amniotic fluid. Bloody amniotic fluid specimens may give false-negative results because of maternal cell contamination.

Stability (blood)

  • Ambient: 1-3 days
  • Refrigerated: 3-5 days

 

Rh Phenotype only: Hemagglutination, Mass Spectrometry.
Approximately 1 week.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login